Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study: Why urban sickle cell patients quit hydroxyurea

Key clinical point: A high percentage of sickle cell patients prescribed hydroxyurea stop taking the drug.

Major finding: More than 34% of patients prescribed the drug stopped taking it.

Study details: Analysis of clinical questionnaires completed by 224 outpatients and electronic medical records.

Disclosures: Dr. Minniti disclosed relationships with Novartis, Global Blood Therapeutics, Teutona, Bluebird Bio, GBT and Bayer.


Minniti C, et al. Abstract no. JSCDH-D-19-00058. Foundation for Sickle Cell Disease Research Symposium; Fort Lauderdale, Fla.; June 9, 2019.